Table S1. Association of Category of Baseline C-Reactive Protein with Development of ESRD, Doubling of Serum Creatinine, Composite of ESRD of Doubling of Serum Creatinine, Composite of ESRD or Death, CV Composite, and Death alone

	Hazard Ratio (95% CI) for ESRD			**P for trend**
Model (Events/Total)	**CRP ≤3.0 mg/L**	**CRP >3.0 to <6.9 mg/L**	**CRP ≥6.9 mg/L**	
Unadjusted (668/4,038)	Ref	1.21 (1.01 - 1.46)	1.37 (1.14 – 1.64)	P=0.001
Adjusted (598/3,642)	Ref	1.08 (0.88 – 1.33)	1.32 (1.07 – 1.63)	P=0.01
Adjusted non-PH[a] (598/3,642)	Ref	1.09 (0.89-1.34)	1.31 (1.06-1.63)	P=0.01
	Hazard Ratio (95% CI) for Doubling of Serum Creatinine			
Model (Events/Total)	**CRP ≤3.0 mg/L**	**CRP >3.0 to <6.9 mg/L**	**CRP ≥6.9 mg/L**	
Unadjusted (428/3,654)	Ref	0.96 (0.76 - 1.22)	1.06 (0.84 – 1.35)	P=0.72
Adjusted (367/3,305)	Ref	0.90 (0.69 – 1.18)	0.94 (0.71 – 1.25)	P=0.84
Adjusted non-PH[b] (367/3,305)	Ref	0.91 (0.69-1.19)	0.95 (0.71-1.26)	P=0.62
	Hazard Ratio (95% CI) for ESRD/Doubling of Serum Creatinine			
Model (Events/Total)	**CRP ≤3.0 mg/L**	**CRP >3.0 to <6.9 mg/L**	**CRP ≥6.9 mg/L**	
Unadjusted (871/4,038)	Ref	1.16 (0.99 - 1.37)	1.28 (1.09 – 1.51)	P=0.002
Adjusted (769/3,642)	Ref	1.05 (0.87 – 1.26)	1.17 (0.97 – 1.42)	P=0.11
Adjusted non-PH[c] (769/3,642)	Ref	1.04 (0.87-1.25)	1.18 (0.97-1.42)	P=0.10
	Hazard Ratio (95% CI) for Death or ESRD			

Model (Events/Total)	**CRP ≤3.0 mg/L**	**CRP >3.0 to <6.9 mg/L**	**CRP ≥6.9 mg/L**	
Unadjusted (1,270/ 4,038)	Ref	1.21 (1.05 - 1.39)	1.57 (1.38 – 1.79)	P<0.001
Adjusted (1,139/ 3,642)	Ref	1.11 (0.96 – 1.29)	1.41 (1.21 – 1.64)	P<0.001
Adjusted non-PH[d] (1,139/ 3,642)	Ref	1.12 (0.96-1.30)	1.40 (1.20-1.63)	P<0.001
	Hazard Ratio (95% CI) for CV Composite Outcome*			
Model (Events/Total)	**CRP ≤3.0 mg/L**	**CRP >3.0 to <6.9 mg/L**	**CRP ≥6.9 mg/L**	
Unadjusted (1,234/ 4,038)	Ref	1.26 (1.09 - 1.45)	1.77 (1.55 – 2.02)	P<0.001
Adjusted (1,111/ 3,642)	Ref	1.16 (0.99 – 1.35)	1.55 (1.34 – 1.81)	P<0.001
Adjusted non-PH[e] (1,111/ 3,642)	Ref	1.16 (0.99-1.35)	1.54 (1.33-1.80)	P<0.001
	Hazard Ratio (95% CI) for Death From Any Cause			
Model (Events/Total)	**CRP ≤3.0 mg/L**	**CRP >3.0 to <6.9 mg/L**	**CRP ≥6.9 mg/L**	
Unadjusted (807/ 4,038)	Ref	1.20 (1.00 – 1.43)	1.85 (1.57 – 2.16)	P<0.001
Adjusted (734/ 3,642)	Ref	1.15 (0.95 – 1.39)	1.59 (1.32 – 1.91)	P<0.001
Adjusted non-PH[f] (734/ 3,642)	Ref	1.15 (0.95-1.39)	1.58 (1.32-1.90)	P<0.001

The multivariable models were adjusted for age, gender, race, estimated GFR, log-transformed urine protein/creatinine ratio, history of acute renal failure, duration of T2DM, HbA1c, retinopathy, insulin use, body mass index,

hemoglobin, serum albumin, coronary artery disease, cerebrovascular disease, peripheral arterial disease, heart failure, systolic blood pressure, low-density lipoprotein concentration, statin therapy, ACE inhibitor or ARB therapy, smoking status, ferritin, transferrin saturation, iron therapy and randomized treatment assignment.
*CV composite included death from any cause, nonfatal MI, stroke, heart failure or hospitalization for myocardial ischemia

In the case of violations of the proportional hazards assumption, time varying coefficients were included in the corresponding multivariable models as follows: [a] race, duration of T2DM, HbA1c, retinopathy, body mass index, estimated GFR, log-transformed urine protein/creatinine ratio, albumin, peripheral arterial disease and low-density lipoprotein; [b] HbA1c and estimated GFR; [c] HbA1c, insulin use, body mass index, albumin and low density lipoprotein; [d] race, log-transformed urine protein/creatinine ratio, albumin, peripheral arterial disease and low-density lipoprotein; [e] age, race, treatment assignment, log-transformed urine protein/creatinine ratio, albumin and ACEi/ARB use; [f] log-transformed urine protein/creatinine ratio and albumin.